Polycystic ovary syndrome presents as a multimorbid condition by age 50: birth cohort linkage to national register data

• Published in: European Journal of Endocrinology
• Main Authors: Kujanpää, Linda, Arffman, Riikka K, Pesonen, Paula, Hurskainen, Elisa, Järvelin, Marjo-Riitta, Franks, Stephen, Tapanainen, Juha S, Morin-Papunen, Laure, Piltonen, Terhi T
• Other Authors: Finnish Medical Foundation, Academy of Finland, Sigrid Juselius Foundation, Finnish Cultural Foundation, Jalmari and Rauha Ahokas Foundation, Päivikki and Sakari Sohlberg Foundation
• Format: Article in Journal/Newspaper
• Language: English
• Published: Oxford University Press (OUP) 2024
• Subjects: Northern Finland
• Online Access: http://dx.doi.org/10.1093/ejendo/lvae057; https://academic.oup.com/ejendo/advance-article-pdf/doi/10.1093/ejendo/lvae057/57846184/lvae057.pdf; https://academic.oup.com/ejendo/article-pdf/190/6/409/58336482/lvae057.pdf

Abstract Objective This population-based follow-up study investigated register-based disease diagnoses and medication use up till age of 50 years among women with polycystic ovary syndrome (PCOS) that were identified from a population-based birth cohort. Design Population-based longitudinal cohort study. Patients Women reporting oligo/amenorrhea and hirsutism at age 31 and/or who were diagnosed with PCOS by a physician by age 46 (n = 244) and women without PCOS symptoms or diagnosis (n = 1556) in the Northern Finland Birth Cohort 1966. Main Outcome Measures National register data on diagnosed diseases (International Statistical Classification of Diseases [ICD]-8-10) and medication use (Anatomical Therapeutic Chemical) until the age of 50. Results Women with PCOS had a 26% higher risk for any registered diagnosis (risk ratio [RR]: 1.26 [1.09-1.46]) and a 24% higher risk for medication use (RR: 1.24 [1.05-1.46]) compared with non-PCOS women, even after adjusting for several confounders. Several main ICD categories were more prevalent among women with PCOS versus non-PCOS controls, eg, endocrine, metabolic, nervous system, musculoskeletal, and genitourinary diseases in addition with different symptoms and injuries. Surprisingly, even though the overall morbidity was only increased in women with PCOS with a body mass index (BMI) ≥ 25 kg/m2, there were several ICD main categories that showed higher comorbidity risk especially in women with PCOS with a BMI < 25 kg/m2. Several medications were prescribed more often to women with PCOS versus non-PCOS controls, eg, medications related to the alimentary tract and metabolism, the cardiovascular system, genitourinary system drugs and sex hormones, dermatologic and hormonal preparations, and medications to treat the musculoskeletal, nervous, and respiratory systems. Conclusion Women with PCOS are burdened with multimorbidity and higher medication use, independent of BMI and other confounders. Accordingly, preventive strategies are needed to alleviate the disease ...